Millennium Management’s Lipocine LPCN Stock Holding History

Millennium Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,059	Closed	-$106K	–	3457
2016 Q2	$106K	Buy	+2,059	New	+$319K	﹤0.01%	3009

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's LPCN Position: Q2 2023 in Review

Millennium Management sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 10,855 shares — an estimated $59K sold.

Millennium Management first reported a position in LPCN in Q2 2014 and held it in 20 quarters. The position peaked at $769K in Q2 2017. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

Millennium Management reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 10,855 Lipocine shares in Q2 2023, an estimated $59K.
Millennium Management first reported a position in Lipocine in Q2 2014 and held it in 20 quarters.
Millennium Management's Lipocine position peaked at $769K in Q2 2017.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.